Tumour Cell-Expressed PD-L1 Reprograms Lipid Metabolism Via EGFR/ITGB4/SREBP1c Signalling in Liver Cancer
Man Zhao,Hongfeng Yuan,Guang Yang,Yufei Wang,Yanan Bu,Huihui Zhang,Lina Zhao,Pan Lv,Haolin Yun,Yu Geng,Jinyan Feng,Chunyu Hou,Shuai Wang,Ningning Zhang,Wei Lu,Xiaodong Zhang
DOI: https://doi.org/10.1016/j.jhepr.2024.101009
2024-01-01
Abstract:Background & Aims: The programmed death-ligand 1 (PD -L1) is a major co -inhibitory checkpoint factor that controls T -cell activities in tumours. PD -L1 is expressed on immune cells and tumour cells. Whether tumour cell -expressed PD -L1 affects tumour cells in an immune cell -independent fashion remains largely elusive. In this study, we investigated the significance of tumour cell -expressed PD -L1 with a focus on downstream signals and changes in lipid metabolism. Methods: Immune -independent functions of PD -L1 in tumour growth were investigated in vitro and in immuno-deficient mice in vivo. The global influence of PD -L1 in targeted/untargeted lipidomic metabolites was studied by comprehensive mass spectrometry -based metabolomic analysis in liver cancer. Effects on lipid metabolism were confirmed by triglyceride and cholesterol assays as well as by Oil Red O staining in liver, pancreatic, breast, and oesophageal squamous cancer. Underlying mechanisms were investigated by real-time quantitative PCR, Western blot analysis, co-immunoprecipitation, pulldown assays, immunofluorescence staining, and RNA sequencing. Results: PD -L1 enhanced the accumulation of triglycerides, cholesterol, and lipid droplets in tumours. PD -L1 influenced targeted/untargeted lipidomic metabolites in hepatoma, including lipid metabolism, glucose metabolism, amino acid metabolism, nucleotide metabolism, and energy metabolism, suggesting that PD -L1 globally modulates the metabolic reprogramming of tumours. Mechanistically, PD -L1 activated epidermal growth factor receptor (EGFR) and/or integrin b4 (ITGB4) by forming a complex of PD-L1/EGFR/ITGB4 in the cell membrane, prior to activating PI3K/mTOR/SREBP1c signalling, leading to reprogramming of lipid metabolism in tumours. Functionally, PD -L1 -mediated lipid metabolism reprogramming supported the tumour growth in vitro and in vivo through EGFR and/or ITGB4 in an immune cell -independent manner. Conclusions: Our findings on lipogenesis and EGFR activation by tumour cell -expressed PD -L1 suggest that, in addition to its immunostimulatory effects, anti -PD -L1 may restrict lipid metabolism and EGFR/ITGB4 signalling in liver cancer therapy. Impact and implications: In this study, we present evidence that PD -L1 drives the reprogramming of lipid metabolism in tumours. PD -L1 forms a complex with epidermal growth factor receptor (EGFR) and ITGB4, activating the PI3K/Akt/mTOR/ SREBP1c signalling pathway and thereby contributing to lipid metabolism in cancer progression. Our findings offer novel insights into the mechanisms by which PD -L1 initiates the reprogramming of lipid metabolism in tumours. From a clinical perspective, the anti -PD -L1 antibody may alleviate resistance to the anti-EGFR antibody cetuximab and inhibit the reprogramming of lipid metabolism in tumours. (c) 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).